Search Results

There are 6140 results for: content related to: Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer

  1. You have free access to this content
    Trastuzumab-containing regimens for metastatic breast cancer

    Intervention Review

    The Cochrane Library

    Sara Balduzzi, Stefania Mantarro, Valentina Guarneri, Ludovica Tagliabue, Vanna Pistotti, Lorenzo Moja and Roberto D'Amico

    Published Online : 12 JUN 2014, DOI: 10.1002/14651858.CD006242.pub2

  2. Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic Breast Cancer

    The Breast Journal

    Volume 19, Issue 2, March/April 2013, Pages: 149–155, Anna S. Berghoff, Zsuzsanna Bago-Horvath, Peter Dubsky, Margaretha Rudas, Ursula Pluschnig, Christoph Wiltschke, Michael Gnant, Guenther G. Steger, Christoph C. Zielinski and Rupert Bartsch

    Version of Record online : 27 JAN 2013, DOI: 10.1111/tbj.12070

  3. You have free access to this content
    Systemic treatment of HER2+ metastatic breast cancer: Clinical conundrums and future perspectives

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S4, June 2014, Pages: 15–25, Richard De Boer, Jane Beith, Jacquie Chirgwin, Sue Chua, Maree Colosimo, Prudence Francis, Michael Green, Ken Pittman, Michelle White, Nicholas Wilcken, Nicholas Zdenkowski and Richard Bell

    Version of Record online : 6 MAY 2014, DOI: 10.1111/ajco.12207

  4. ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective

    Medicinal Research Reviews

    Volume 32, Issue 1, January 2012, Pages: 166–215, Ruchi Saxena and Anila Dwivedi

    Version of Record online : 25 OCT 2010, DOI: 10.1002/med.20209

  5. You have free access to this content
    Management of patients with HER2-positive metastatic breast cancer: Is there an optimal sequence of HER2-directed approaches?

    Cancer

    Volume 121, Issue 1, January 1, 2015, Pages: 17–24, Amelia B. Zelnak and Kari B. Wisinski

    Version of Record online : 23 JUL 2014, DOI: 10.1002/cncr.28815

  6. Effects of lapatinib and trastuzumab on vascular endothelial growth factor in experimental corneal neovascularization

    Clinical & Experimental Ophthalmology

    Volume 43, Issue 5, July 2015, Pages: 449–457, Mehmet K Kaya, Tamer Demir, Hakan Bulut, Nusret Akpolat and Burak Turgut

    Version of Record online : 24 JUN 2015, DOI: 10.1111/ceo.12500

  7. Trastuzumab containing regimens for early breast cancer

    Intervention Review

    The Cochrane Library

    Lorenzo Moja, Ludovica Tagliabue, Sara Balduzzi, Elena Parmelli, Vanna Pistotti, Valentina Guarneri and Roberto D'Amico

    Published Online : 18 APR 2012, DOI: 10.1002/14651858.CD006243.pub2

  8. You have free access to this content
    Systemic treatment of HER2-positive metastatic breast cancer: A systematic review

    Asia-Pacific Journal of Clinical Oncology

    Volume 10, Issue S4, June 2014, Pages: 1–14, Nicholas Wilcken, Nicholas Zdenkowski, Michelle White, Ray Snyder, Ken Pittman, Paul Mainwaring, Michael Green, Prudence Francis, Richard De Boer, Maree Colosimo, Sue Chua, Jacquie Chirgwin, Jane Beith and Richard Bell

    Version of Record online : 6 MAY 2014, DOI: 10.1111/ajco.12206

  9. You have free access to this content
    Current and emerging targeted therapies for metastatic breast cancer

    Cancer

    Volume 118, Issue 12, 15 June 2012, Pages: 3014–3025, Edith A. Perez and Jean-Philippe Spano

    Version of Record online : 17 OCT 2011, DOI: 10.1002/cncr.26356

  10. You have free access to this content
    Biomarkers of drugs targeting HER-family signalling in cancer

    The Journal of Pathology

    Volume 232, Issue 2, January 2014, Pages: 219–229, Filippo Montemurro and Maurizio Scaltriti

    Version of Record online : 10 DEC 2013, DOI: 10.1002/path.4269

  11. You have free access to this content
    Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells

    International Journal of Cancer

    Volume 127, Issue 3, 1 August 2010, Pages: 696–706, Jeanett Fischgräbe, Martin Götte, Katharina Michels, Ludwig Kiesel and Pia Wülfing

    Version of Record online : 3 DEC 2009, DOI: 10.1002/ijc.25076

  12. You have free access to this content
    Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge

    European Journal of Heart Failure

    Volume 14, Issue 2, February 2012, Pages: 130–137, Carlo G. Tocchetti, Gianluca Ragone, Carmela Coppola, Domenica Rea, Giovanna Piscopo, Stefania Scala, Claudia De Lorenzo, Rosario V. Iaffaioli, Claudio Arra and Nicola Maurea

    Version of Record online : 18 FEB 2014, DOI: 10.1093/eurjhf/hfr165

  13. Biomedical Applications of Trastuzumab: As a Therapeutic Agent and a Targeting Ligand

    Medicinal Research Reviews

    Volume 35, Issue 4, July 2015, Pages: 849–876, Hitesh Kulhari, Deep Pooja, Sri V. K. Rompicharla, Ramakrishna Sistla and David J. Adams

    Version of Record online : 1 APR 2015, DOI: 10.1002/med.21345

  14. You have free access to this content
    Systemic therapy for early-stage HER2-positive breast cancers: Time for a less-is-more approach?

    Cancer

    Volume 121, Issue 4, February 15, 2015, Pages: 517–526, Elisavet Paplomata, Rita Nahta and Ruth M. O'Regan

    Version of Record online : 24 OCT 2014, DOI: 10.1002/cncr.29060

  15. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth

    Journal of Cellular Physiology

    Volume 226, Issue 1, January 2011, Pages: 52–57, Alejandro Vazquez-Martin, Cristina Oliveras-Ferraros, Silvia Cufí, Sonia Del Barco, Begoña Martin-Castillo and Javier A. Menendez

    Version of Record online : 23 JUL 2010, DOI: 10.1002/jcp.22333

  16. You have free access to this content
    Adjuvant targeted therapy in early breast cancer

    Cancer

    Volume 115, Issue 6, 15 March 2009, Pages: 1154–1168, John Mackey, Deanna McLeod, Joseph Ragaz, Karen Gelmon, Sunil Verma, Kathleen Pritchard, Kara Laing, Louise Provencher and Lauren F. Charbonneau

    Version of Record online : 22 JAN 2009, DOI: 10.1002/cncr.24114

  17. You have free access to this content
    Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer

    Cancer

    Volume 116, Issue 12, 15 June 2010, Pages: 2856–2867, Helena R. Chang

    Version of Record online : 1 APR 2010, DOI: 10.1002/cncr.25120

  18. You have free access to this content
    Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors

    Cytometry Part A

    Volume 79A, Issue 9, September 2011, Pages: 684–693, Simone Diermeier-Daucher, Stefanie Breindl, Stefan Buchholz, Olaf Ortmann and Gero Brockhoff

    Version of Record online : 22 JUL 2011, DOI: 10.1002/cyto.a.21107

  19. You have free access to this content
    Calpain4 is required for activation of HER2 in breast cancer cells exposed to trastuzumab and its suppression decreases survival and enhances response

    International Journal of Cancer

    Volume 131, Issue 10, 15 November 2012, Pages: 2420–2432, Sucheta Kulkarni, Leya Saju, Carol Farver and Raymond Tubbs

    Version of Record online : 28 MAR 2012, DOI: 10.1002/ijc.27510

  20. Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer

    Clinical Pharmacology & Therapeutics

    Volume 87, Issue 5, May 2010, Pages: 586–592, E C Dijkers, T H Oude Munnink, J G Kosterink, A H Brouwers, P L Jager, J R de Jong, G A van Dongen, C P Schröder, M N Lub-de Hooge and E G de Vries

    Version of Record online : 31 MAR 2010, DOI: 10.1038/clpt.2010.12